February 7, 2018 / 9:55 PM / 3 months ago

BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months

Feb 7 (Reuters) - Psivida Corp:

* PSIVIDA’S SECOND PHASE 3 STUDY FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS MAINTAINS POSITIVE EFFICACY AND SAFETY PROFILE AT 12 MONTHS

* PSIVIDA CORP - HIGHLY SIGNIFICANT DIFFERENCE BETWEEN DURASERT AND SHAM IN PREVENTION OF UVEITIS RECURRENCE AT 12 MONTHS IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below